A 40-day boycott of Target began on Wednesday after Black faith leaders encouraged their congregations to respond to the company's shift away from its diversity, equity and inclusion policies ...

Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi ...

Whalen, PhD, poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 ... vulnerability that may be a potential target for new therapeutics. Mutations in BRCA1 ...

Baird lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $20 from $24 and keeps an Outperform rating on the shares. The firm said the Q4 Amtagvi numbers were disappointing but ...

If any team was going to turn Sunday afternoon's highly anticipated showdown between No. 7 UConn and No. 4 South Carolina into a blowout, the money would have been on the defending national ...

Musk’s posts serve as “merely a trigger mechanism” to his followers, Donovan said, often prompting them to scour social media profiles, look up information about a target’s family members ...

JD Vance called veteran journalist Mehdi Hasan a “dummy” on Monday after he appeared to point to the vice president’s hypocrisy for saying European “commissars” are suppressing free ...

“We hope that therapies that target this window of vulnerability will have tremendous scope in preventing recurrence in patients with early cancer at risk of recurrence.” This could mean more ...

Other equities analysts have also issued reports about the stock. Chardan Capital reduced their target price on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating ...

Burga is a general assignment reporter at TIME. Facade of Target store with bold red signage on Jan. 18, in San Ramon, Calif. Facade of Target store with bold red signage on Jan. 18, in San Ramon ...

Based on your own experience, how does the efficacy and safety profile of nivolumab (Opdivo) plus ipilimumab (Yervoy) compare with immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) regimens for ...